A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 22
- Registration Number
- NCT06433557
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, London, United Kingdom
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Phase 2
Recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for Navepegritide
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 72
- Registration Number
- NCT06079398
- Locations
- 🇬🇧
Ascendis Investigational Site, London, United Kingdom
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 140
- Registration Number
- NCT05929807
- Locations
- 🇮🇪
Ascendis Pharma Investigational Site, Dublin, Ireland
🇵🇹Ascendis Investigational Site, Coimbra, Portugal
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05598320
- Locations
- 🇪🇸
Ascendis Pharma Investigational Site, Vitoria, Spain
© Copyright 2025. All Rights Reserved by MedPath